US · TMCI
Treace Medical Concepts, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Ponte Vedra, FL 32081
- Website
- treace.com
Price · as of 2025-12-31
$1.86
Market cap 118.52M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $29.34 | +1,477.42% |
| Intrinsic Value(DCF) | $0.66 | -64.52% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $18.81 | $37.45 | $1,752.12 | $0.00 | $0.00 |
| 2022 | $24.07 | $36.67 | $781.60 | $0.00 | $0.00 |
| 2023 | $13.13 | $32.09 | $237.51 | $0.00 | $0.00 |
| 2024 | $8.57 | $28.34 | $12.43 | $0.00 | $0.00 |
| 2025 | $1.66 | $29.34 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Treace Medical Concepts, Inc.'s (TMCI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $29.34
- Current price
- $1.86
- AI upside
- +1,477.42%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.66
-64.52% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TMCI | Treace Medical Concepts, … | $1.86 | 118.52M | +1,477% | -65% | — | — | -1.78 | 1.20 | 0.49 | -1.64 | -53.40 | 1.56 | 79.81% | -25.46% | -27.74% | -58.94% | -67.77% | -28.95% | 0.16 | -10.18 | 4.31 | 2.95 | -0.08 | 333.00% | 159.00% | -3953.00% | -28.08% | -0.52 | -36.90% | 0.00% | 0.00% | 52.40% | -1.30 | -2.40 | 0.33 | -0.40 |
| BVS | Bioventus Inc. | $8.78 | 588.05M | +221% | -58% | — | — | -1890.78 | 4.06 | 1.05 | 22.83 | — | -2.28 | 67.72% | -2.09% | -5.85% | -0.20% | -2.20% | -0.04% | 2.27 | -0.31 | 1.31 | 0.80 | 7.50 | -7912.00% | 1189.00% | 37343.00% | 6.28% | 0.18 | 7.76% | 0.00% | 0.00% | 10.62% | -74.74 | 23.69 | 1.56 | 0.82 |
| CBLL | CeriBell, Inc. | $18.67 | 692.58M | +73% | +350% | — | — | -12.42 | 3.80 | 7.45 | -10.25 | — | 3.82 | 87.89% | -65.57% | -59.97% | -29.21% | -202.59% | -25.36% | 0.14 | -30.90 | 9.73 | 9.08 | 0.33 | -5693.00% | 3609.00% | 1427.00% | -6.27% | -2.13 | -144.22% | 0.00% | 0.00% | 0.00% | -9.04 | -12.70 | 5.93 | 17.63 |
| EHAB | Enhabit, Inc. | $13.61 | 689.9M | +90% | -75% | — | — | -2.78 | 0.82 | 0.41 | -11.59 | -2.98 | -0.99 | 48.71% | -11.12% | -15.09% | -25.81% | -9.68% | -11.58% | 1.09 | -2.68 | 1.53 | 1.41 | -6.47 | 9317.00% | -110.00% | 557.00% | 11.07% | 0.41 | 4.09% | 0.00% | 0.00% | 9.71% | -8.42 | 20.45 | 0.94 | 1.09 |
| EOLS | Evolus, Inc. | $4.30 | 278.73M | +754% | +521% | — | — | -16.70 | 152.52 | 3.16 | -35.41 | — | -13.07 | 68.46% | -12.92% | -18.94% | 664.86% | -75.16% | -23.92% | 23.54 | -1.84 | 2.40 | 2.14 | -1.72 | -2500.00% | 3176.00% | -4536.00% | -2.31% | -0.29 | -42.53% | 0.00% | 0.00% | 2.46% | -25.72 | -45.46 | 3.32 | -0.33 |
| KIDS | OrthoPediatrics Corp. | $19.17 | 480.73M | +230% | -49% | -91% | — | -11.37 | 1.30 | 1.91 | -55.63 | -373.01 | 2.61 | 73.05% | -12.27% | -16.78% | -11.31% | -8.28% | -8.08% | 0.14 | -4.84 | 5.55 | 2.48 | -3.66 | 305.00% | 1545.00% | -6136.00% | -3.54% | -0.11 | -4.56% | 0.00% | 0.00% | 1.84% | -15.12 | -27.47 | 1.85 | 2.35 |
| LAB | Standard BioTools Inc. | $1.13 | 434.56M | +2,535% | -50% | -88% | +606% | -5.60 | 0.99 | 4.92 | -2.77 | — | 0.99 | 49.86% | -109.34% | -87.77% | -16.72% | -23.68% | -12.69% | 0.07 | -3588.65 | 4.19 | 1.86 | 0.92 | -6154.00% | -5108.00% | -4555.00% | -19.69% | -0.69 | -34.48% | 0.00% | 0.00% | 0.00% | -2.82 | -3.18 | 3.08 | 2.09 |
| RXST | RxSight, Inc. | $7.48 | 307.55M | +291% | -36% | -74% | — | — | 1.14 | 2.33 | -2.43 | — | 1.14 | 76.60% | -35.84% | -28.96% | 0.00% | -83.88% | 0.00% | 0.04 | -1204.75 | 10.95 | 9.58 | 0.22 | 3380.00% | -389.00% | -1360.00% | -6.17% | -0.59 | -33.66% | 0.00% | — | 1.44% | -2.00 | -4.98 | 0.72 | 3.16 |
| SMLR | Semler Scientific, Inc. | $20.33 | 310.75M | +321% | +54% | +196% | — | 6.57 | 1.17 | 4.78 | 11.81 | 6.92 | 16.68 | 91.55% | 37.19% | 72.65% | 27.04% | 15.50% | 25.73% | 0.00 | — | 3.59 | 3.06 | -0.41 | 9506.00% | -1744.00% | 1881.00% | 9.06% | 3.87 | 21.12% | 0.00% | 0.00% | 0.00% | 12.13 | 10.43 | 4.51 | 18.96 |
| SRDX | Surmodics, Inc. | $42.98 | 614.51M | +203% | -62% | -97% | — | -49.05 | 4.76 | 4.49 | 118.28 | -7.60 | 11.17 | 73.81% | -4.48% | -9.15% | -9.67% | -5.14% | -6.34% | 0.28 | -1.59 | 3.96 | 3.09 | -0.61 | 64545.00% | -491.00% | -14271.00% | -0.57% | 0.01 | -2.95% | 0.00% | 0.00% | 0.00% | -99.07 | -172.40 | 4.44 | 7.30 |
| TOI | The Oncology Institute, I… | $2.89 | 284.32M | +772% | +1,754% | — | — | -1.01 | 14.97 | 0.14 | -2.36 | — | -2.91 | 13.73% | -15.28% | -16.44% | -174.89% | -70.35% | -27.75% | 34.31 | -8.02 | 2.15 | 1.88 | -1.37 | -2283.00% | 2133.00% | -2582.00% | -56.44% | -0.51 | -35.49% | 0.00% | 0.00% | 23.64% | -2.12 | -4.19 | 0.32 | 0.03 |
About Treace Medical Concepts, Inc.
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
- CEO
- John T. Treace
- Employees
- 477
- Beta
- 0.77
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.66 ÷ $1.86) − 1 = -64.52% (DCF, example).